Detail of "117976-89-3"

CAS Number:
117976-89-3
Name:
1H-Benzimidazole,2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-
Superlist Name:
Rabeprazole
Molecular Structure:
Formula:
C₁₈H₂₁N₃O₃S
Molecular Weight:
359.4426
Deleted CAS:
909251-57-6
Synonyms:
2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole;1H-benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-;2-({[4-(3-Methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole;Pariprazole;(RS)-2-([4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole;
Density:
1.33 g/cm³
Boiling Point:
603.9 °C at 760 mmHg
Flash Point:
319.1 °C
Solubility:
Soluble Details

Famous Chemical Enterprises

Livzon
Total
Shell
Dupont
Exxonmobil
Akzonobel
Basf
Bayer
BP

Other Products

Supplier Location
Supplier Location
- China (Mainland)(15)
- India(10)
- United States(5)
- Canada(1)
- Pakistan(1)
- United Kingdom(1)
Business Type
Business Type
- Lab/Research institutions(1)
- Manufacturers(1)
- Trading Company(19)
Certificates
Certificates
- ISO(1)
- Production License (0)

Please post your buying leads>>

Display：

Manufacturer
Enterprise Authentication
Suppiers of more reward points first
New supplier

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Reference

Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study: Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. Pehlivanov, N. D.; Olyaee, M.; Sarosiek, I.; McCallum, R. W. (Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA). Alimentary Pharmacology and Therapeutics, 18(9), 883-890 (English) 2003 Blackwell Publishing Ltd. CODEN: APTHEN. ISSN: 0269-2813. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Aim: To assess the effect of timing of rabeprazole (RB) 20 mg/d administration on esophageal acid exposure and nocturnal gastric acid breakthrough (NGAB) in patients with gastro-esophageal reflux disease (GERD). Methods: 20 GERD patients received two 7-day treatments of RB in the morning (a.m.) or in the evening (p.m.) hours. The regimens were randomized in a double-blind fashion and sepd. by a 7-day washout period. The tablets were taken 30 min before standardized meals. A combined (esophageal & gastric) 24-h pH monitoring was performed before and on day 7 of each treatment. Results: Total esophageal acid exposure was normalized in 10/14 (71.4%) patients with RB p.m. and in 6/15 (42.8%) with RB a.m. RB p.m. significantly decreased the nocturnal supine esophageal acid exposure vs. RB a.m., 0.2% vs. 3.4%. The mean NGAB duration was significantly shortened with RB a.m. and p.m. vs. the baseline recording, 4.1±1.8 and 3. 117976-89-3 which is the cas registry number of some chemical is mentioned.4±1.5 h vs. 7.8±1.7 h. Conclusions: Rebeprazole significantly reduced the NGAB duration and significantly increased the mean nocturnal gastric pH; RB p.m. normalized more effectively the total esophageal exposure than RB-a.m.; RB p.m. provided significantly better control of nocturnal supine gastro-esophageal reflux than a.m. dosing. These data suggest that administration of a PPI before the evening meal maximizes acid control and would be the preferred dosing schedule in GERD patients, particularly those with nocturnal symptoms. .

Efficacy of a 1-week rabeprazole triple therapy for eradicating Helicobacter pylori and ulcer healing: an 'in-clinical-practice' study: Efficacy of a 1-week rabeprazole triple therapy for eradicating Helicobacter pylori and ulcer healing: an 'in-clinical-practice' study. Goh, K. L.; Rosaida, M. S.; Salem, O.; Cheah, P. L.; Ranjeev, P.; Tan, Y. M.; Rosmawati, M.; Chin, S. C. (Department of Medicine, University of Malaya, Kuala Lumpur, Malay.). Chinese Journal of Digestive Diseases, 4(4), 204-208 (English) 2003 Blackwell Publishing Asia Pty Ltd. CODEN: CJDDA9. ISSN: 1443-9611. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) OBJECTIVE: To det. the efficacy and tolerability of a 1-wk treatment regimen consisting of rabeprazole and two antibiotics, clarithromycin and amoxicillin, in the eradication of Helicobacter pylori in an 'in-clin.-practice' setting. METHODS: Patients selected had unequivocal evidence of H. pylori infection based on urease test and histol. of antral and corpus biopsies obtained at endoscopy. Patients with complicated ulcers were not included. Patients received rabeprazole 10 mg b.i.d., clarithromycin 500 mg b.i.d. and amoxicillin 1 g b.i.d. for 1 wk and were assessed for successful eradication at least 4 wk after completion of therapy by repeat gastroscopy and gastric biopsies. Eradication was defined as absence of bacteria in both antral and corpus biopsies tested by histol. and urease test. Ulcer patients did not receive continued acid suppression therapy following the 1-wk course of treatment. RESULTS: The study recruited 205 patients of whom 25 were not compliant with the medications or defaulted on follow-up and were therefore not included in the per-protocol anal. Eradication of H. pylori was successful in 166/180 of patients on per-protocol anal. (92.2% [95% CI: 87.3, 95.7]) and in 169/205 patients on intention-to-treat anal. 81103-11-9 and 117976-89-3 are also in the experiment. (82.4% [95% CI: 80.5, 90.2]; P = 1.000). There were 47 patients with active ulcers: DU 27, GU 18, DU/GU 2. Overall, ulcer healing was achieved in 42 of 44 (95.5%) patients who had successful eradication of H. pylori infection, but ulcers did not heal in any of the three patients (DU 2, GU 1) who did not eradicate the infection. Of the total group, 199 were assessed for compliance and side-effects of treatment. Side-effects were in general mild and tolerable. Of 14 patients who were not compliant with medication; 4 (2.0%) attributed it to side-effects of treatment (increased abdominal pain, dizziness and taste disturbances) and the remaining 10 did not give specific reasons. The most common side-effect was bitter taste, reported by 39.2% of patients. Other side-effects, such as giddiness, increased abdominal pain, lethargy, loose bowel motions and skin rash, were mild and found in only a small percentage of patients. CONCLUSIONS: The rabeprazole 1-wk triple therapy with amoxicillin and clarithromycin is effective in eradicating H. pylori in an 'in-clin.-practice' setting. The treatment was well tolerated by patients. Good ulcer healing was achieved with short-course H. pylori eradication therapy without the need for continued acid suppression. .

Detail of "117976-89-3"

1H-Benzimidazole,2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-

Famous Chemical Enterprises

Related products

Other Products

Supplier Location

Business Type

Certificates

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

CAS No.117976-89-3 Rabeprazole

Reference